Intraoperative cell transplantation for congestive heart failure: experience in China
Hao Zhang1, Ying-jie Wei, Sheng-shou Hu
1Research Center for Cardiac Regenerative Medicine, Ministry of Health, and Department of Cardiac Surgery, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Insights
Cell-based regenerative medicine offers a promising treatment for congestive heart failure (CHF). Intraoperative cell transplantation shows potential for repairing damaged heart muscle in millions of patients needing advanced cardiac therapies.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Cell Therapy
Background:
- Congestive heart failure (CHF) remains a significant global health issue despite management advancements.
- Cell-based regenerative medicine presents a promising therapeutic avenue for CHF patients.
- Over 5 million individuals in China may require cell-based therapies for myocardial repair.
Purpose of the Study:
- To summarize preclinical and clinical achievements in intraoperative cell transplantation for CHF.
- To outline future research directions in cardiac cell therapy within China.
Main Methods:
- Review of preclinical studies on intraoperative cell transplantation.
- Analysis of clinical trial data for cell therapy in CHF patients.
- Evaluation of cardiac surgery's role in heart cell therapy.
Main Results:
- Significant progress has been made in both preclinical and clinical studies of intraoperative cell transplantation.
- Cardiac surgery is increasingly integrated with cell therapy approaches in China.
- The potential for cell-based therapies to repair or replace damaged myocardium has been demonstrated.
Conclusions:
- Intraoperative cell transplantation is a viable and advancing strategy for managing CHF.
- Further research is warranted to optimize cell-based therapies for myocardial regeneration.
- The integration of cell therapy with cardiac surgery holds substantial promise for future CHF treatment.
Abstract:
Despite significant improvement in the management of congestive heart failure (CHF), it still is a major worldwide public health problem. Currently, cell-based regenerative medicine has been developed as a promising therapeutic option for patients with CHF. Considering the large and growing population, it is estimated that over 5 million patients in China may need such a cell-based therapy to replace or repair the damaged myocardium. Cardiac surgery has emerged as an important player in heart cell therapy in China in recent years. Here, we summarize our achievements in both preclinical and clinical studies of intraoperative cell transplantation, and present our understanding of future research in this attractive field.
